Novocure Reports 8% Revenue Growth in 2025, FDA Approves Optune Pax for Pancreatic Cancer
Event summary
- Novocure reported $655.4 million in total net revenues for 2025, an 8% year-over-year increase.
- The U.S. FDA approved Optune Pax for locally advanced pancreatic cancer in February 2026.
- Active patients on TTFields therapy reached 4,620 globally as of December 31, 2025.
- Novocure's gross margin decreased to 76% in Q4 2025, down from 79% in Q4 2024.
- The company expects 2026 revenues between $675 million and $705 million.
The big picture
Novocure's 2025 financial results reflect steady growth in its core TTFields therapy, particularly with the FDA approval of Optune Pax for pancreatic cancer, a significant strategic win in a challenging therapeutic area. The company's focus on expanding into new indications and markets, coupled with its push for profitability, positions it to capitalize on the growing demand for innovative cancer treatments. However, operational efficiencies and regulatory hurdles remain critical factors in its long-term success.
What we're watching
- Revenue Diversification
- How the contribution from Optune Lua and Optune Pax will impact overall revenue growth.
- Regulatory Milestones
- The timeline for FDA decisions on additional indications and the impact on market expansion.
- Operational Efficiency
- Whether Novocure can sustain profitability improvements amid rising R&D and marketing expenses.
Related topics